IMPACT Medicom

Dr. Carolyn Owen, Chair of the Canadian Hematology Consensus Group (CHCG), introduces the CHCG and discusses its mission to develop evidence-based Canadian consensus recommendations in areas of unmet need in hematology. In this video, Dr. Owen highlights the group’s multidisciplinary expert panel, rigorous methodology, and current initiatives, including consensus papers on relapsed/refractory follicular lymphoma and first-line diffuse large B-cell lymphoma.The CHCG was founded by Anna Christofides, President of IMPACT Medicom Inc. and Founder & Managing Director of the CHCG, to provide the scientific and operational infrastructure required to develop high-quality Canadian consensus recommendations and support knowledge translation in hematology.Learn more about the CHCG:www.canadianconsensusgroup.com

In this episode with Dr Robert Puckrin, we discuss the unmet needs of double-exposed patients with CLL/SLL, as well as the current and novel treatments that can address this gap. Our guestDr. Puckrin is a Hematologist and Clinician Investigator at the Arthur Child Comprehensive Cancer Centre and Alberta Blood and Marrow Transplant Program. He is also a clinical assistant professor at the University of Calgary. Dr Puckrin has received honoraria for advisory boards and/or speaking engagements from Abbvie, Astrazeneca, BeOne, Eli Lilly, Incyte, Kite, Janssen,Pfizer, Roche, and Seagen.Please provide your feedback on this episode by filling out this quick survey at the following link: https://survey.decipherinc.com/survey/selfserve/53b/g00e/2511135Funding for this episode was provided by Eli Lilly Canada.This information is intended solely for educational purposes and is not intended to promote the use of any Eli Lilly Canada medication. All materials or information provided by Eli Lilly Canada Inc. for this learning program comply with applicable regulatory standards.​Editorial control of this learning program resides with the speaker within the parameters of the Innovative Medicines Canada Code and Eli Lilly Policy.Eli Lilly Canada supports discussion of its products consistent with the approved prescribing information in the product monograph.Any off-label discussion of products represents the personal opinion of the speaker.​

In this podcast episode, Dr. Dimitrios Coutsinos describes a video capsule series involving three educational videos of lung resections using minimally invasive video-assisted thoracic surgery (VATS) following neoadjuvant immunotherapy in patients with lung cancer. Our Host:Dr. Dimitrios Coutsinos is a thoracic surgeon at Interior Health Authority and a professor at the University of British Columbia. Dr. Coutsinos has received honoraria for advisory board attendance from: AstraZeneca, Bristol Myers Squibb, Intuitive Surgica, Johnson and Johnson, Merck, and Roche.Video Capsule Series:To access the video capsule series, please visit: https://www.impactmedicom.com/video-capsules.This podcast episode and video capsule series was funded by Merck Canada.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com.

In this podcast episode, we discuss clinical trial updates in chronic lymphocytic leukemia from the 2025 European Hematology Association annual congress in Milan, Italy and the 18th International Conference on Malignant Lymphoma in Lugano, Switzerland. The discussion involves an analysis of the data from abstracts investigating combination and novel therapies for the treatment of CLL.Our Host:Dr. Constantine Tam is Head of Lymphoma Service at Alfred Health and Professor of Haematology at Monash University in Melbourne, Australia. Prior to joining Alfred, Dr. Tam completed a Leukemia Fellowship at MD Anderson Cancer Centre in Houston, Texas and served as Disease Group Lead for Low Grade Lymphoma and CLL at Peter MacCallum Cancer Centre & Royal Melbourne Hospital for over 10 years. He is the global lead for the BTK inhibitor zanubrutinib, overseeing its development from the first human dosed to international licensing studies. He also played key roles in the first global study of ibrutinib and venetoclax in CLL and the pivotal study of Tisagenlecleucel in diffuse large B-cell lymphoma.Our guests:Dr. John Gribben is Consultant Hematologist and Medical Oncologist at the Barts Cancer Institute, Barts NHS Trust and Professor in Medical Oncology at The London School of Medicine, Queen Mary University of London, in London, UK. Dr. Gribben trained in Haematology at University College London and in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, where he remained on the faculty for 17 years before returning to the UK. Dr. Gribben serves on many international committees, including as Chair of the international workshop for NHL, co-Chair of the international workshop for CART, and founding member of the CLL Research Consortium. He also serves as an executive board member of the European Hematology Association, where he previously served as President from 2019-2021.Dr. Stephan Stilgenbauer is professor of medicine and Medical Director of the Comprehensive Cancer Center Ulm (CCCU), Head Early Clinical Trials Unit (ECTU), and Head Division of CLL Dept. of Internal Medicine III at Ulm University, Germany. He received his medical training at Heidelberg Medical School, Germany, and was trained in internal medicine and hematology-oncology at the Universities of Heidelberg and Ulm. He spent a postdoctoral fellowship at the German Cancer Research Center (DKFZ) in Heidelberg. His research focus is on the molecular pathogenesis and evolution as well as development of novel treatment strategies in hematological malignancies.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/)

(FRENCH) In this podcast episode, which follows this introduction in French, Dr Christopher Lemieux summarizes a paper by Dr Abramson, et al. on the management of Peripheral Neuropathy Associated with Brentuximab Vedotin in the Frontline Treatment of classical Hodgkin Lymphoma.Our GuestDr Lemieux is a Hematologist at the Centre hospitalier universitair de Québec-Université Laval. He is also a member of the immunocellular therapy network fellowship program at Université Laval. This podcast episode was sponsored by Pfizer Canada Inc.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma. Our GuestDr. Michael Chu is a clinician scientist at the Cross Cancer Institute and an Associate Professor at the University of Alberta in Edmonton, Alberta.This podcast episode was sponsored by Pfizer Canada Inc.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Versha Banerji, a Canadian hematologist from Manitoba and Dr. Jennifer Brown, an internationally renowned hematologist from the United States, discuss data on the treatment of CLL presented at the American Society of Hematology (or ASH) meeting in San Diego, CA. The discussion involves an analysis of the data from 8 presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is put into the Canadian context, with key take-aways that are relevant to practice in Canada.  Our Guests:Dr. Versha Banerji is a hematologist at Max Rady College of Medicine at the University of Manitoba in Winnipeg, Manitoba.Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest:Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.comThis episode was funded by Eli Lilly, Canada. 

In this podcast episode, three of Canada’s top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis of the data from 6 oral presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is put into the Canadian context, with key take-aways that are relevant to practice in Canada.  Our Guests:Dr. Versha Banerji from Max Rady College of Medicine at the University of Manitoba in Winnipeg, Manitoba chairs the meeting. Dr. Banerji is joined by Dr Sarit Assouline, from the Jewish General Hospital in Montreal, Quebec and Dr. Christopher Hillis, from McMaster University in Hamilton, Ontario. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/)

In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss  updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examined the efficacy and safety of sonrotoclax plus zanubrutinib for the treatment of R/R CLL. Our Guest:Dr. Stephen Opat is the director of Clinical Haematology at Monash Health, founder and chair of the Australasian Lymphoma and Related Diseases Registry and lead investigator of the Melbourne Genomics Health Alliance Lymphoma Flagship.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer vaccines and new targeted therapies.Our Guest:Dr. Barbara MeloskyDr Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group and is creator and chair of the British Columbia Lung Cancer Biobank. This podcast episode was sponsored by Sanofi Aventis Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker (pathologist) discuss the latest biomarkers that may inform treatment of upper GI cancer. Our Guests:Dr. Christine Brezden-MasleyDr.  Brezden-Masley is a Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health System in Toronto, Canada. Dr. Catherine StreutkerDr.  Streutker is a Professor in the Department of Laboratory Medicine & Pathobiology at the University of Toronto.This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule version: https://www.youtube.com/watch?v=uk5JEUjbkDE&t=127s.  Our Guest:Dr. S. Mark Taylor is a Facial Plastic and Reconstructive surgeon in Halifax, Nova Scotia. He is currently a Professor of Surgery at Dalhousie University. His expertise and clinical interest includes rhinoplasty/nasal surgery, eyelid surgery, management of facial paralysis, facial skin cancer, facial reconstruction, and surgery of the aging face.Note: The faculty for this program had full editorial control of the content.The following program was funded by Sanofi.Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this podcast episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant. Our guest:Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease.Note: The faculty for this program had full editorial control of the content.The following program was funded by Sanofi.Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice.Our Guests:Dr. Rami Kotb is a physician in the Division of Hematology, Department of Medical Oncology & Hematology at CancerCare Manitoba, Winnipeg, MB, CanadaDr Donna Reece is the Director and a Professor of Medicine in the Program for Multiple Myeloma and Related Diseases at the University Health Network. She is also a Professor of Medicine at the University of Toronto and Princess Margaret Hospital in Toronto, ON, CanadaNote: A link to the abstract at ASH can be found here: https://ash.confex.com/ash/2023/webprogram/Paper190168.htmlThis podcast episode was sponsored by Sanofi-Aventis Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this episode of our podcast, recorded at the American Society of Hematology (ASH) in San Diego, California, we discuss  updated results of the ALPINE trial with Dr. Jennifer Brown. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. Our Guest:Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.Note: The ALPINE trial is published in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this video capsule series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.This fifth episode of the series was recorded live from ESMO 2023 with Dr. Thomas Powles, who presented results of the EV-302 trial, and Dr. Normand Blais, Dr. Srikala Sridhar, and Dr. Bernie Eigl, who discussed the impact of new data from trials on 1L LA/mUC .Our Guests:Dr. Thomas Powles: Dr Thomas Powles is a Professor of Genitourinary Oncology and Director of the Barts Cancer Centre at St. Bartholomew's Hospital. He is also the Lead for Solid Tumour Research in London, England. Dr. Normand Blais: Dr  Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.Dr. Srikala Sridhar: Dr  Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. Dr. Bernie Eigl: Dr. Eigl is a medical oncologist specializing in genitourinary oncology, with a special research interest in bladder and prostate cancers at BC Cancer. He ia alo a Clinical Associate Professor at the University of British Columbia.This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.In this fourth and final episode taken from the webinar, Drs Normand Blais, Terence Friedlander, and Srikala Sridhar provide their perspective on the management of the first-line treatment locally advanced metastatic urothelial carcinoma, including a discussion of the optimal use of enfortumab vedotin plus pembrolizumab and management of associated adverse events. Our Guests:Dr. Normand Blais: Dr  Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.Dr. Terence Friedlander: Dr  Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.Dr. Srikala Sridhar: Dr  Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.In this third episode taken from the webinar, Dr. Srikala Sridhar presents a clinical case on the treatment of locally advanced metastatic urothelial carcinoma, highlighting the role of enfortumab vedotin plus pembrolizumab in the treatment plan. Our Guests:Dr. Normand Blais: Dr  Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.Dr. Terence Friedlander: Dr  Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.Dr. Srikala Sridhar: Dr  Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto.In this second episode taken from the webinar, Dr. Terrence Friedlander presents clinical data in the first-line setting and provides a US perspective on how he manages the treatment of locally advanced metastatic urothelial carcinoma.  Our Guests:Dr. Normand Blais: Dr  Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.Dr. Terence Friedlander: Dr  Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.Dr. Srikala Sridhar: Dr  Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto. In this first episode taken from the webinar, Dr. Normand Blais introduces the speakers and discusses the unmet needs of patients with locally advanced metastatic urothelial carcinoma in Canada. Our Guests:Dr. Normand Blais: Dr  Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.Dr. Terence Friedlander: Dr  Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases.Dr. Srikala Sridhar: Dr  Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. The full webinar can be found on our website at: https://www.impactmedicom.com/video-capsules. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

Welcome to our podcast episode on external quality assurance (or eQA) for testing biomarkers in oncology, hosted by Anna Christofides. In this episode,  we discuss with Dr. Emina Torlakovic, the use of eQA to aid in the improvement of biomarker testing in Canada . Our Guest: Dr. Emina Torlakovic is a Professor in Department of Laboratory Medicine and Pathobiology at the University of Toronto. She is also a Staff Hematopathologist and Director of Biomarker Development and Quality Assurance at the University Health Network. Dr. Torlakovic is also a founding member of NordiQC, Canadian Immunohistochemistry Quality Control (CIQC), as well as the International Society for Immunohistochemistry and Molecular Morphology. She is Chair of the Canadian Association of Pathologists’ National Standards Committee for High Complexity Testing and also co-directs CIQC. This podcast episode was sponsored by Merck, Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this fourth episode, we discuss the management of hyperglycemia associated with enfortumab vedotin, or EV.Our Guests:This fourth episode on the management of neuropathy is hosted by Dr Nimira Alimohamed, Medical Oncologist at the Tom Baker Cancer Centre, Calgary, AB and Clinical Assistant Professor in the Department of Medicine at the University of Calgary.  In this episode, Dr Alimohamed interviews Dr. Minna Woo, Professor in the Departments of Medicine, Institute of Medical Science, Immunology, and Pharmacology and Toxicology at the University of Toronto and Director of the Banting & Best Diabetes Centre. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this second episode, we discuss the management of skin reactions associated with enfortumab vedotin, or EV. Our Guests:In this episode, Dr. Normand Blais, who is a medical oncologist and Director of clinical research in thoracic oncology at the CHUM and adjunct professor at McGill University in Montreal, QC interviews dermatology specialist, Dr. Joel Claveau. Dr. Joel Claveau is a dermatologist specializing in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University guides us through this discussion. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this first episode, we discuss the evolution of therapy from chemotherapy to treatment with novel therapies such as enfortumab vedotin, or EV. We then focus on the key clinical trials examining the efficacy and safety of EV for the treatment of urothelial carcinoma. Our Guests:We introduce the topic in our first episode with Dr. Normand Blais, who is a medical oncologist and Director of clinical research in thoracic oncology at the CHUM and adjunct professor at McGill University in Montreal, QC. Dr. Joel Claveau, a dermatologist specializing in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University guides us through this discussion. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this third episode, we discuss the management of peripheral neuroptathy associated with enfortumab vedotin, or EV.Our Guests:This third episode on the management of neuropathy is hosted by Dr Srikala Sridhar, Professor in the Department of Medicine at the University of Toronto and a Genitourinary Medical  Oncologist at the Princess Margaret Cancer.  In this episode, Dr Sridhar interviews Dr Warren Mason, a Professor in the department of medicine at the University of Toronto and a neuro-oncologist at the Princess Margaret Cancer Center. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the latest updates in the treatment of CLL with Dr. Laurie Sehn, Dr. Matthew Davies, and Dr. Constantine Tam. Our Guests:Dr. SehnDr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. Dr. DavidsDr Davids is the Director of Clinical Research at the Division of Lymphoma at the Dana Farber Institute and Associate Professor of Medicine at Harvard Medical School.Dr. TamDr. Constantine Tam is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the results of the ALPINE trial with Dr. Matthew Davies. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. In this episode, Dr. Davids discusses the impact of the results of the ALPINE trial for clinical practice given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory CLL and SLL.Our Guest:Dr Davids is the Director of Clinical Research at the Division of Lymphoma at the Dana Farber Institute and Associate Professor of Medicine at Harvard Medical School. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to our 13th podcast episode in the Precision Medicine Series. In this episode, hosted by Anna Christofides,  we discuss diagnostic, prognostic and predictive biomarkers for the treatment of endometrial cancer.  Our Guests:Dr. Jessica McAlpine, a Gynaecologic Oncologist and Division Head in the Division of Gynaecologic Oncology at the University of British ColumbiaDr. Mary Kinloch, a Gynaecologic Pathologist and Division Head of Pathology and Laboratory Medicine at the University of Saskatchewan This podcast episode was sponsored by Merck Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Live From ASH, New Orleans:In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the American Society of Hematology meeting in New Orleans. Our Guest:Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. In this episode, Dr. Sehn discusses the impact of the results of the ALPINE trial for clinical practice in Canada given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Live From ASH, New Orleans:In this episode, Dr. Jennifer Brown discusses results of the phase 3 ALPINE trial, presented as a late breaking abstract at the American Society of Hematology (ASH) meeting 2022 in New Orleans, LA. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582. Our Guest:Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to our 12th episode in the precision medicine in oncology podcast series. In this episode we discuss diagnostic, prognostic and predictive biomarkers for the treatment of breast cancer.Our Guest: Our guest for this episode is Dr. David Cescon,  a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Ontario, where his clinical practice is devoted to the care of patients with breast cancer.  This podcast episode was sponsored by Merck Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to our podcast episode on the treatment of urothelial carcinoma. In this episode, hosted by Anna Christofides, we  discuss updated results of the Phase 3 EV-301 trial, presented at ASCO 2022, that examined the efficacy and safety of Enfortumab Vedotin, or EV, versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.  Our Guest:Our guest for this episode is Dr Nimira Alimohamed, Medical Oncologist and Clinical Associate Professor of Medicine at the University of Calgary and Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this episode, we discuss immunotherapy treatment and biomarker testing for metastatic cervical cancer.  Our Guest:Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynecology at Dalhousie University, Halifax, Canada. Dr. Bentley is Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC) and the Society of Canadian Colposcopists (SCC). He is also Past-President of the Society of Gynecologic Oncology of Canada (GOC). He serves on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer. This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this episode of IMPACT Medicom’s podcast series on immunotherapies in Head and Neck Squamous Cell Carcinoma, we discuss the medical oncologist’s role in managing patients with HNSCC, and how immunotherapies fit in to their practice.Our Guest:Dr. Martin Smoragiewicz is a Medical Oncologist at the Odette Cancer Centre, part of Sunnybrook Health Sciences Centre in Toronto, Ontario. His clinical expertise is in Genitourinary and Head & Neck cancers and his research focuses on improving therapeutics, with a special interest in immunotherapy. Dr. Smoragiewicz is the principal investigator on numerous clinical trials, and the lead for Head & Neck clinical trials at the Odette Cancer Centre.This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to episode 11 of our Precision Medicine in Oncology series. In this episode, we discuss the development of a pan-Canadian consensus paper on the selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer.Our Guest:Our guest for this episode is Dr. Anna Tinker, Medical Oncologist at BC Cancer in Vancouver, Canada. Dr. Tinker is also a Clinical Associate Professor in the Department of Medicine at the University of British Columbia.This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to the second episode of IMPACT Medicom’s podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas (HNSCC). This episode includes a discussion of:The role of the surgical oncologist in managing patients with HNSCCHow immunotherapy fits into to the surgical oncologist's practice  Our Guest:Our guest is Dr. Antoine Eskander, a head and neck surgical oncologist at Sunnybrook Health Sciences Centre and Assistant professor in the department of otolaryngology at the University of Toronto. He is also an adjunct scientist at the Institute for Clinical Evaluative Sciences. This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

Welcome to the first episode of IMPACT Medicom’s podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas. This episode includes a discussion of:The role of the pathologist in the management of head and neck cancers PD-L1 testing as a predictive biomarker for immunotherapy in HNSCCImproving the testing process for PD-L1 Our Guest:Our guest is Dr. Matthew Cecchini, Pathologist in the Department of Pathology and Laboratory Medicine at London Health Sciences Centre and  Assistant Professor at Western University in London Ontario Canada. Dr. Cecchini  specializes in pulmonary, head and neck, and molecular pathology. His research interests include the application of digital and machine learning tools in pathology. This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this episode, we discuss the treatment of triple negative breast cancer (TNBC) with Dr. Stephen Chia. We cover:The use of immunotherapies to treat TNBCBiomarkers that can determine which patients will best respond to immunotherapiesThe challenges of testing for PDL-1Our Guest:Dr. Stephen Chia is a professor in the division of medical oncology and staff medical oncologist with BC Cancer, in Vancouver. He has held many leadership roles at BC Cancer, including Head of the Division of Medical Oncology UBC, Head of the Department of Clinical Research, BC Cancer, and Chair of the BC Cancer Breast Tumour Group. He has also been the Co-Chair of the Breast Disease Site for Canadian Cancer Trials Group (CCTG). This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this episode of IMPACT Medicom’s Precision Medicine in Oncology podcast series, we discuss the evolving biomarker landscape in gastrointestinal malignancies and some of the advantages and challenges of implementing and accessing biomarker testing. Our guest:Dr. Rosalyn Juergens is a medical oncologist with clinical expertise in lung and esophageal cancer. She was on the faculty at The Johns Hopkins Medical Institute from 2007-2010 until she joined the faculty at McMaster University in 2011. Dr. Juergens’ leadership roles include serving as chair of the Lung Disease Site Team and Head of the Department of Clinical Trials at the Juravinski Cancer Centre in Hamilton, Ontario. She is also the chair of the Executive Committee of the Canadian Cancer Trials Group Investigational New Drug Committee and Medical Advisory Committee Chair for Lung Cancer Canada. Dr. Juergens’ research interests involve improving therapeutics and diagnostics in cancer, with a focus on developmental therapeutics and Phase I and II clinical trials.This podcast episode was sponsored by Merck Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

Welcome to episode 9 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the second episode in a 3-part series on ovarian cancer. This episode, hosted by IMPACT Medicom’s Sarah Doucette, features a debate on whether first-line maintenance therapy with PARP inhibitors can be considered a curative strategy in patients with advanced, BRCA-mutated epithelial ovarian cancer. Our Guests:Dr. Taymaa May Taymaa May is a surgical scientist at the University Health Network and an Associate Professor at the University of Toronto. Dr. May is the surgical oncology lead for Toronto central south, Ontario Health/Cancer Care Ontario and the chair of the Gynecologic Oncology Group of Ontario. She is the director of clinical specialty programs in the department of surgical oncology and a member of the Princess Margaret executive. She is also the current chair of the Gynecologic Oncology of Canada’s (GOC) Annual General Meeting and is a member of GOC’s board of directors. Dr. May’s research focuses on surgical innovation and translational research in ovarian cancer.Dr. James Bentley Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynaecology at Dalhousie University. He is a Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC), the Society of Gynaecologic Oncology of Canada (GOC), and the Society of Canadian Colposcopists, and is the past Chair of the Royal College Nucleus Committee for Gynecologic Oncology. He continues to serve on numerous national and provincial committees involved with cervical cancer screening and gynecological cancer. Dr. Bentley's clinical interests lie in the field of cervical cancer prevention, colposcopy, clinical trials including the application of HPV Vaccines and chemotherapy trials.Links:SOLO-1 5-year update: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00531-3/fulltextCorrelation between BRCA status and surgical cytoreduction: https://www.gynecologiconcology-online.net/article/S0090-8258(21)00540-0/fulltextThis podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to episode 8 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the first in a series of episodes focusing on ovarian cancer. In this episode, we discuss the importance of BRCA testing for patients with advanced epithelial ovarian cancer and how national initiatives have helped to improve BRCA testing standards across the country. Our Guests:Dr. Janice Kwon, Gynecologic Oncologist at Vancouver Coastal Health and Vice Head and Professor in the Department of Obstetrics and Gynecology at the University of British Columbia. Dr. Kwon serves as Chair of both the Priority and Evaluations Committee at BC Cancer and the National BRCA Collaborative. Her expertise is in hereditary cancer syndromes and conducting cost-effectiveness analyses of testing criteria and risk-reducinginterventions.Dr. Alon Altman, Gynecologic Oncologist and Professor at the University of Manitoba, and the Winnipeg Health Sciences Centre/Cancercare Manitoba.  Dr. Altman is the president elect for the Society of Gynecologic Oncology of Canada (the GOC). He is actively involved in multiple other university, national and international committees including serving as program director for the department of Obstetrics and Gynecology, chair of the University Medical Group (UMG), vice chair for the Medical Management Safety Committee (MMSC) at CancerCare Manitoba, and Gynecologic oncology track lead for the FIGO 2021 Scientific planning committee.This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this seventh episode of our podcast series on precision medicine, hosted by Anna Christofides, we discuss genomic testing in prostate cancer. Our episode focuses on the evolution and uptake of genetic testing in prostate cancer. We discuss testing for homologous recombination repair (HRR) genes and their association with prognosis and influence on treatment decisions. We also discuss somatic vs germline testing and who is responsible for ordering genomic tests. Our guest:Our guest on today’s episode is Dr. Neil Fleshner, who is the Martin Barkin Chair and a Professor of Surgery at the Division of Urology at the University of Toronto in Toronto, Ontario. He is also affiliated with Sunnybrook Hospital, Mount Sinai Hospital, Princess Margaret Cancer Centre (UHN), and the Toronto General Hospital (UHN).This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Welcome to episode 6 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology. In this episode Dr. Gonzalez discusses testing methodology, particularly for mismatch repair deficiency, as well as potential emerging biomarkers for metastatic colorectal cancer. Our Guest: Dr. Raul Gonzalez is an Associate Professor of Pathology at Harvard Medical School and the Director of Gastrointestinal Pathology at Beth Israel Deaconess Medical Center in Boston, Massachusetts.  Dr. Gonzalez is a surgical pathologist specializing in gastrointestinal pathology. He is the Editor- in-Chief of Pathology Outlines and the Reviews Editor for Histopathology. He also serves as the Vice Chair for the College of American Pathologists Surgical Pathology Committee and the Website Committee Chair for the Hans Popper Hepatopathology Society.This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

In this episode of our podcast, we discuss the use of zanubrutinib for the treatment of Waldenstrom’s Macroglobulinemia.  Our episode discusses data from the Phase 3 ASPEN trial, comparing the efficacy and safety of zanubrutinib with ibrutinib in these patients. Our GuestsOur first guest, Dr. Constantine Tam, is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. He is also the lead author on the ASPEN trial, and provides a detailed look at the key data from this study.  We are then joined by Dr. Carolyn Owen, an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. Dr. Owen discusses the potential impact of the data from the ASPEN trial on Canadian clinical practice. And how zanubrutinib may fit into the Canadian treatment algorithm for Waldenstrom’s Macroglobulinemia. This podcast episode was sponsored by Beigene Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss:·       The current standards for molecular testing in metastatic colorectal cancer·       The potential benefit of a Canadian guideline for molecular testing in metastatic colorectal cancerOur guest:Dr. Sharlene Gill is Professor of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver. Dr. Gill earned her MD from the University of British Columbia and completed a fellowship in gastrointestinal oncology at the Mayo Clinic (Rochester, MN). She also received a Master of Public Health degree from the Harvard School of Public Health and completed her MBA at the Kenan-Flagler School of Business at the University of North Carolina. Dr. Gill currently specializes in the treatment of gastrointestinal malignancies and serves as the Chair of the Canadian Clinical Trials Group GI Disease Site Committee. In addition, she is President-Elect of the Canadian Association of Medical Oncologists and is Editor-in-Chief for the peer-reviewed journal Current Oncology. This podcast episode was sponsored by Merck Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

BackgroundLung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics) Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer cases in Canada are stage 4 at diagnosis. (2020 Canadian Cancer Statistics) Two clinical trials, the Dutch-Belgian screening trial (NELSON) and the United States National Lung Screening Trial (NLST), have demonstrated the value of lung cancer screening in reducing mortality rates in high-risk populations. The lung cancer community across Canada is therefore united in the belief that screening programs should be implemented nationwide. Lung Cancer Screening programs have been announced across Canada. The Ontario program launched in April 2021 and the program in Quebec launched in June 2021. A program in BC was announced in 2020 and will launch in the near future. Other provinces across Canada are working on developing screening programs also. In this podcast series, we discuss the importance of lung cancer screening and aim to raise awareness of these programs in Canada in order to improve patient care. Our GuestsDr. Donna Maziak: Thoracic surgeon and surgical oncologist at the Ottawa Hospital, Ottawa, Ontario.  Chantal Bornais: Nurse navigator at the Ottawa Hospital, Ottawa, Ontario.  ResourcesLakeridge Health in Oshawa: https://www.lakeridgehealth.on.ca/en/central-east-regional-cancer-program/lung-cancer-screening-pilot.aspThe Ottawa Hospital: https://www.ottawahospital.on.ca/en/clinical-services/deptpgrmcs/programs/cancer-program/what-we-offer-our-programs-and-services/lung-screening/Health Sciences North in Sudbury: https://www.hsnsudbury.ca/portalen/rcp/hrlcspPrincess Margaret Hospital in Toronto: https://www.trcp.ca/en/screening/screening-programs/Pages/lung.aspxCancer Care Ontario: https://www.cancercareontario.ca/enTO FIND A SCREENING PROGRAM NEAR YOU: https://right2survive.ca/resource-centre/screening/ If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

BackgroundLung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics) Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer cases in Canada are stage 4 at diagnosis. (2020 Canadian Cancer Statistics) Two clinical trials, the Dutch-Belgian screening trial (NELSON) and the United States National Lung Screening Trial (NLST), have demonstrated the value of lung cancer screening in reducing mortality rates in high-risk populations. The lung cancer community across Canada is therefore united in the belief that screening programs should be implemented nationwide. Lung Cancer Screening programs have been announced across Canada. The Ontario program launched in April 2021 and the program in Quebec launched in June 2021. A program in BC was announced in 2020 and will launch in the near future. Other provinces across Canada are working on developing screening programs also. In this podcast series, we discuss the importance of lung cancer screening and aim to raise awareness of these programs in Canada in order to improve patient care. Our GuestsDr. Stephen Lam: Professor of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer. Dr. Lam is a Distinguished Scientist, and Leon Judah Blackmore Chair in Lung Cancer Research at the BC Cancer Research Center. He was the recipient of the Friesen-Rygiel Award for Outstanding Canadian Academic Discovery and the Gustav Killian Medal by the World Association of Bronchology for his pioneering contributions to the field of early lung cancer diagnosis, the Distinguished Achievement Award from the University of British Columbia and the Joseph Cullen Award for life-time scientific achievements in lung cancer prevention research by the International Association for the Study of Lung Cancer. Dr. Rakesh Patel: General practitioner from Silverado Medical Clinic in Calgary, Alberta. ResourcesBC Press release http://www.bccancer.bc.ca/about/news-stories/news/2020/b-c-launches-lung-cancer-screening-program-%E2%80%93-the-first-in-canadaCPAC Report: https://s22457.pcdn.co/wp-content/uploads/2021/01/lung-cancer-screening-environmental-scan-2019-2020-Jan132021-EN.pdfTO FIND A SCREENING PROGRAM NEAR YOU: https://right2survive.ca/resource-centre/screening/ If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

Renseignements générauxLe cancer du poumon est l’une des formes de cancer les plus courantes ainsi que la principale cause de décès par cancer au Canada. (Statistiques canadiennes sur le cancer, 2020).Le taux de survie des patients atteints d’un cancer du poumon est faible. La survie nette à trois ans est de 71 % pour les cas diagnostiqués au stade 1, et chute à 5 % pour les cas diagnostiqués au stade 4. Au Canada, environ la moitié des cancers du poumon ont atteint le stade 4 au moment du diagnostic. (Statistiques canadiennes sur le cancer, 2020).Deux études cliniques, soit l’étude néerlando-belge sur le dépistage NELSON et une étude américaine nationale sur le dépistage du cancer du poumon (l’étude NLST), ont montré l’utilité du dépistage du cancer du poumon dans la réduction du taux de mortalité chez les populations à haut risque.Au Canada, il y a consensus au sein de la communauté du cancer du poumon quant à la nécessité de mettre en œuvre des programmes de dépistage à l’échelle nationale.On a annoncé la mise en œuvre de programmes de dépistage du cancer du poumon à l’échelle du Canada. L’Ontario et le Québec ont lancé les leurs en avril et en juin 2021, respectivement. La Colombie-Britannique a fait l’annonce de son programme en 2020; celui-ci sera lancé sous peu. D’autres provinces travaillent également à l’élaboration de programmes de dépistage. Dans cette série de balados, nous discuterons de l’importance du dépistage du cancer du poumon et des moyens de faire connaître ces programmes au Canada afin d’améliorer les soins offerts aux patients.Invités Dre Nicole Bouchard: Pneumologue au département de médecine de l’Université de Sherbrooke, Québec.Dr Richard Dumouchel:  Omnipraticien à la Clinique médicale du Coteau, à Saint-Jean-sur-Richelieu, Québec. Résources https://right2survive.ca/resource-centre/screening/https://www.quebec.ca/en/health/advice-and-prevention/screening-and-carrier-testing-offer/lung-cancer-screening-demonstration-project  If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

BackgroundLung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics) Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer cases in Canada are stage 4 at diagnosis. (2020 Canadian Cancer Statistics) Two clinical trials, the Dutch-Belgian screening trial (NELSON) and the United States National Lung Screening Trial (NLST), have demonstrated the value of lung cancer screening in reducing mortality rates in high-risk populations. The lung cancer community across Canada is therefore united in the belief that screening programs should be implemented nationwide. Lung Cancer Screening programs have been announced across Canada. The Ontario program launched in April 2021 and the program in Quebec launched in June 2021. A program in BC was announced in 2020 and will launch in the near future. Other provinces across Canada are working on developing screening programs also. In this podcast series, we discuss the importance of lung cancer screening and aim to raise awareness of these programs in Canada in order to improve patient care. Our Guests Dr. Paul Wheatley-Price: Associate Professor in the Department of Medicine at the University of Ottawa and Medical Oncologist at The Ottawa Hospital Cancer Centre, specializing in the treatment of thoracic malignancies and carcinoma of unknown primary. Since 2016, Dr. Wheatley-Price has previously served as President of Lung Cancer Canada. Dr. Jeffery Habert: General practitioner in Thornhill, ON and Assistant Professor in the Department of Family and Community Medicine at the University of Toronto. ResourcesONTARIOLakeridge Health in Oshawa: https://www.lakeridgehealth.on.ca/en/central-east-regional-cancer-program/lung-cancer-screening-pilot.aspThe Ottawa Hospital: https://www.ottawahospital.on.ca/en/clinical-services/deptpgrmcs/programs/cancer-program/what-we-offer-our-programs-and-services/lung-screening/Health Sciences North in Sudbury: https://www.hsnsudbury.ca/portalen/rcp/hrlcspPrincess Margaret Hospital in Toronto: https://www.trcp.ca/en/screening/screening-programs/Pages/lung.aspxBRITISH COLUMBIAThe BC Lung Screen Trial: http://www.bccancer.bc.ca/our-research/participate/lung-healthCPAC Report: https://s22457.pcdn.co/wp-content/uploads/2021/01/lung-cancer-screening-environmental-scan-2019-2020-Jan132021-EN.pdfTO FIND A SCREENING PROGRAM NEAR YOU: https://right2survive.ca/resource-centre/screening/ If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.